S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
Is Gold Really Boring? (Ad)
3 Warren Buffett Stocks that are Moving into the Buy Zone
3 Stocks That Really, Really Need the Defense Bill to Pass
Is Gold Really Boring? (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Stock market today: Futures climb as a miserable month for US markets nears its end. Crude nears $92
Is Gold Really Boring? (Ad)
AI Race Accelerates with Amazon's Investment In Anthropic
This Little Known Automaker May Save Your Life and Your Portfolio
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
Is Gold Really Boring? (Ad)
3 Warren Buffett Stocks that are Moving into the Buy Zone
3 Stocks That Really, Really Need the Defense Bill to Pass
Is Gold Really Boring? (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Stock market today: Futures climb as a miserable month for US markets nears its end. Crude nears $92
Is Gold Really Boring? (Ad)
AI Race Accelerates with Amazon's Investment In Anthropic
This Little Known Automaker May Save Your Life and Your Portfolio
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
Is Gold Really Boring? (Ad)
3 Warren Buffett Stocks that are Moving into the Buy Zone
3 Stocks That Really, Really Need the Defense Bill to Pass
Is Gold Really Boring? (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Stock market today: Futures climb as a miserable month for US markets nears its end. Crude nears $92
Is Gold Really Boring? (Ad)
AI Race Accelerates with Amazon's Investment In Anthropic
This Little Known Automaker May Save Your Life and Your Portfolio
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
Is Gold Really Boring? (Ad)
3 Warren Buffett Stocks that are Moving into the Buy Zone
3 Stocks That Really, Really Need the Defense Bill to Pass
Is Gold Really Boring? (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Stock market today: Futures climb as a miserable month for US markets nears its end. Crude nears $92
Is Gold Really Boring? (Ad)
AI Race Accelerates with Amazon's Investment In Anthropic
This Little Known Automaker May Save Your Life and Your Portfolio
ASX:TLX

Telix Pharmaceuticals (TLX) Stock Forecast, Price & News

Compare
Today's Range
N/A
50-Day Range
A$41.24
▼
A$49.92
52-Week Range
N/A
Volume
746,789 shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileChartCompetitorsInsider TradesHeadlines

TLX stock logo

About Telix Pharmaceuticals (ASX:TLX) Stock

Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company focuses on developing diagnostic and therapeutic products using MTR. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of kidney cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase I/II clinical trials for the treatment of glioblastoma (brain cancer); and TLX66, which is in Phase I/IIa clinical trials for the treatment of bone marrow conditioning and rare diseases. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; TLX591-Sx, a positron emission tomography (PET) tracer that delivers PET and fluorescent (optical) imaging; and TLX599-CDx, an investigational prostate cancer imaging agent that uses single photon emission computed tomography. It has a strategic license and commercial partnership with Mauna Kea Technologies and Lightpoint Medical to develop advanced image and radio-guided surgical technologies. The company was founded in 2015 and is headquartered in North Melbourne, Australia.


TLX Stock News Headlines

September 19, 2023 | fool.com.au
Who wants to be a millionaire? 3 ASX shares I think that could make it happen
September 19, 2023 | fool.com.au
Who wants to be a millionaire? 3 ASX shares I think could make it happen
September 27, 2023 | Wall Street Fundamentals (Ad)
The "Plug and Play" Model Putting Online Giants to Shame
While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."
August 24, 2023 | fool.com.au
ASX 200 healthcare stock Telix Pharmaceuticals surges 12% on ‘excellent result’
August 23, 2023 | finanznachrichten.de
Telix Pharmaceuticals Limited: Telix 2023 Half-Year Results: Revenue and Earnings Growth Marks Transition to a Sustainable Commercial-Stage Company
July 19, 2023 | fool.com.au
Why is the Telix share price crashing 17% today?
July 19, 2023 | finance.yahoo.com
Telix Reports Continued Double-Digit Revenue Growth and Positive Operating Cash Flow
June 26, 2023 | finanznachrichten.de
Telix Pharmaceuticals Limited: New ZIRCON Phase III Data Presented at SNMMI: Potential Utility of TLX250-CDx in Staging and Monitoring ccRCC
September 27, 2023 | Wall Street Fundamentals (Ad)
The "Plug and Play" Model Putting Online Giants to Shame
While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."
June 22, 2023 | reuters.com
Australia's Telix Pharma hits record high after buying UK medical devices firm
June 22, 2023 | finance.yahoo.com
Telix to Showcase ZIRCON Phase III Kidney Cancer Imaging Data and Theranostic Pipeline Developments at SNMMI
June 21, 2023 | finanznachrichten.de
Telix Pharmaceuticals Limited: Telix to Expand Late-Stage Urologic Pipeline with Acquisition of Lightpoint Medical
June 21, 2023 | finance.yahoo.com
Telix to Expand Late-Stage Urologic Pipeline with Acquisition of Lightpoint Medical
June 20, 2023 | finanznachrichten.de
Telix Pharmaceuticals Limited: Telix Urology Innovation Showcase to be held at The Yale Club, New York City
June 20, 2023 | finance.yahoo.com
Telix Urology Innovation Showcase to be held at The Yale Club, New York City
June 19, 2023 | finanznachrichten.de
Telix Pharmaceuticals Limited: First Patient Dosed in Phase II STARBURST Study of TLX250-CDx Exploring Indication Expansion
June 15, 2023 | finance.yahoo.com
Telix Briefing: Innovation in Urology to Feature Key Opinion Leaders in Prostate and Kidney Cancer
June 8, 2023 | finanznachrichten.de
Telix Pharmaceuticals Limited: Telix Opens European Radiopharmaceutical Production Facility
June 8, 2023 | afr.com
Aussie nuclear medicine firm breaks into EU amid huge growth
June 8, 2023 | finance.yahoo.com
Telix Opens European Radiopharmaceutical Production Facility
June 8, 2023 | finance.yahoo.com
TLX.AX - Telix Pharmaceuticals Limited
May 25, 2023 | finance.yahoo.com
Telix to Host Briefing with U.S. Leadership Team and Key Opinion Leaders to Highlight Innovation in Urology
May 7, 2023 | finanznachrichten.de
Telix Pharmaceuticals Limited: Telix to Supply Bayer with Illuccix® for Global Phase III Prostate Cancer Study
May 7, 2023 | finance.yahoo.com
Telix to Supply Bayer with Illuccix® for Global Phase III Prostate Cancer Study
May 7, 2023 | finance.yahoo.com
Telix to Supply Bayer with Illuccix® for Global Phase III Prostate Cancer Study, including Japanese Sites
May 3, 2023 | msn.com
Why has the Telix Pharmaceuticals share price rocketed 53% in a month?
May 1, 2023 | finance.yahoo.com
First Patients in Canada Imaged with Illuccix®: Now Commercially Available Nationwide
See More Headlines
Receive TLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Telix Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
ASX
Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
ASX:TLX
CUSIP
N/A
CIK
N/A
Web
www.telixpharma.com
Phone
61 4 4914 8448
Fax
N/A
Employees
234
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
A($0.15)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-47,510,000.00
Net Margins
-13.31%
Pretax Margin
N/A
Return on Equity
-52.36%
Return on Assets
5.18%

Debt

Debt-to-Equity Ratio
17.23
Current Ratio
1.54
Quick Ratio
3.00

Sales & Book Value

Annual Sales
$356.88 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
8.35
Book Value
A$0.24 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
319,520,000
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
2.31
Ten Starter Stocks For Beginners to Buy Now Cover
Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Dr. Christian P. Behrenbruch BEng(Hons) (Age 48)
    DPhil(Oxon), GAICD, J.D., M.B.A., MBA, Co-Founder, MD, Group CEO & Exec. Director
    Comp: $599.23k
  • Mr. Darren Smith B.Bus. (Age 58)
    FCPA, M.B.A., Group Chief Financial Officer
    Comp: $245.86k
  • Dr. Andreas Kluge M.D.
    Ph.D., Chief Medical Advisor & Director (Leave of Absence)
  • Dr. Colin Hayward FFPM
    MBBS, Group Chief Medical Officer
  • Mr. Richard Valeix M.B.A.
    Group Chief Commercial Officer
  • Dr. Michael Wheatcroft B.Sc.
    BSc(Hons), Ph.D., Ph.D., (Cantab), Chief Scientist
  • Mr. Craig Ulrick
    Chief Information Officer
  • Ms. Kyahn Williamson B.A.
    Sr. VP of Corp. Communications & Investor Relations
  • Ms. Melanie Farris (AGIA
    ACG, ACIS) BComn, B.Com., GradDip, M.A.I.C., Sr. VP of Global Governance, Risk & Compliance
  • Ms. Lena Moran-Adams L.L.B.
    Gen. Counsel

Key Competitors

View All Competitors

Insiders

View All Insider Transactions













TLX Stock - Frequently Asked Questions

What other stocks do shareholders of Telix Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Telix Pharmaceuticals investors own include ACADIA Pharmaceuticals (ACAD), Adverum Biotechnologies (ADVM), Aimmune Therapeutics (AIMT), ANI Pharmaceuticals (ANIP), AxoGen (AXGN), Biohaven (BHVN), bluebird bio (BLUE), Blueprint Medicines (BPMC), Calithera Biosciences (CALA) and Codexis (CDXS).

What is Telix Pharmaceuticals' stock symbol?

Telix Pharmaceuticals trades on the ASX under the ticker symbol "TLX."

How much money does Telix Pharmaceuticals make?

Telix Pharmaceuticals (ASX:TLX) has a market capitalization of $0.00 and generates $356.88 million in revenue each year. The company earns $-47,510,000.00 in net income (profit) each year or A($0.15) on an earnings per share basis.

How many employees does Telix Pharmaceuticals have?

The company employs 234 workers across the globe.

How can I contact Telix Pharmaceuticals?

Telix Pharmaceuticals' mailing address is 55 Flemington Road, Suite 401, North Melbourne, VIC 3051, Australia. The official website for the company is www.telixpharma.com. The company can be reached via phone at 61 4 4914 8448.

This page (ASX:TLX) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -